Figure 5

Gefitinib treatment restores the chemosensitivity in HepG2 cells. A: HepG2 cells were treated with Gefitinib 10 μg/ml and EGFR as well as pERK protein expression was assessed by Western blot. B: HepG2 cells were treated with Gefitinib 10 μg/ml, Gemcitabine 114 μg/ml, Gemcitabine 114 μg/ml plus Gefitinib 10 μg/ml, Doxorubicin 0.15 μg/ml and Doxorubicin 0.15 μg/ml plus Gefitinib 10 μg/ml. ABC-transport protein mRNA expression was determined by RT PCR. Columns average of three independent experiments, bars SD. ^†p ≤ 0.05; ^††p ≤ 0.001 compared to the untreated control group; *p ≤ 0.05; **p ≤ 0.001 compared to monotherapy.